Patents by Inventor Robert Carnahan

Robert Carnahan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CROSS-REACTIVE CORONAVIRUS ANTIBODIES AND USES THEREOF
    Publication number: 20230348571
    Abstract: The present disclosure relates to antibodies and uses thereof for treating, preventing, and detecting coronavirus infection.
    Type: Application
    Filed: April 6, 2021
    Publication date: November 2, 2023
    Inventors: Ivelin Stefanov Georgiev, Andrea R. Shiakolas, Kevin J. Kramer, James E. Crowe, Jr., Robert Carnahan, Nianshuang Wang, Daniel Wrapp, Jason McLellan
  • HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
    Publication number: 20230122364
    Abstract: The present disclosure is directed to antibodies binding to and neutralizing tire coronavirus designated SARS-CoV-2 and methods for use thereof.
    Type: Application
    Filed: March 26, 2021
    Publication date: April 20, 2023
    Inventors: James E. CROWE, Jr., Seth ZOST, Robert CARNAHAN, Pavlo GILCHUK
  • HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
    Publication number: 20220281958
    Abstract: The present disclosure is directed to antibodies binding to and neutralizing the coronavirus designated SARS-CoV-2 and methods for use thereof.
    Type: Application
    Filed: March 18, 2022
    Publication date: September 8, 2022
    Applicant: Vanderbilt University
    Inventors: James E. CROWE, JR., Seth ZOST, Robert CARNAHAN, Pavlo GILCHUK
  • Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
    Patent number: 11345741
    Abstract: The present disclosure is directed to antibodies binding to and neutralizing the coronavirus designated SARS-CoV-2 and methods for use thereof.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: May 31, 2022
    Assignee: Vanderbilt University
    Inventors: James E. Crowe, Jr., Seth Zost, Robert Carnahan, Pavlo Gilchuk
  • HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
    Publication number: 20210300999
    Abstract: The present disclosure is directed to antibodies binding to and neutralizing the coronavirus designated SARS-CoV-2 and methods for use thereof.
    Type: Application
    Filed: March 25, 2021
    Publication date: September 30, 2021
    Applicant: Vanderbilt University
    Inventors: James E. CROWE, JR., Seth ZOST, Robert CARNAHAN, Pavlo GILCHUK
  • HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
    Publication number: 20210277092
    Abstract: The present disclosure is directed to antibodies binding to and neutralizing the coronavirus designated SARS-CoV-2 and methods for use thereof.
    Type: Application
    Filed: February 11, 2021
    Publication date: September 9, 2021
    Applicant: Vanderbilt University
    Inventors: James E. Crowe, JR., Seth Zost, Robert Carnahan, Pavlo Gilchuk
  • Methods of using an antibody to inhibit WNT-mediated signaling in cancer
    Patent number: 9175090
    Abstract: The present invention is directed to monoclonal antibodies and fragments thereof directed to LRP5/6 that find use in the prevention and treatment of cardiac remodeling and cancer. Also disclosed are methods for using such monoclonal antibodies in the prevention and treatment of such diseases.
    Type: Grant
    Filed: July 29, 2014
    Date of Patent: November 3, 2015
    Assignee: VANDERBILT UNIVERSITY
    Inventors: Ethan Lee, Pampee P. Young, Josiane Eid, Robert Carnahan, Curtis Thorne, Kelly Meyers